MktsMarkets

Elicio Therapeutics, Inc.
NASDAQ: ELTXKey statistics
ELTX News
Stories mentioning ELTX from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | ||||||||
| Cost of Goods Sold | ||||||||
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | ||||||||
| Research & Development | 6,757 | 5,080 | 5,039 | 7,006 | 7,778 | 10,709 | 7,208 | 8,180 |
| Sales General & Admin | ||||||||
| Total Operating Expenses | ||||||||
| Operating Income (Loss) | (10,602) | (8,842) | (8,045) | (10,091) | (10,736) | (13,477) | (10,344) | (10,924) |
| Interest Income | 157.00 | 199.00 | 168.00 | 210.00 | 185.00 | 137.00 | ||
| Interest Expense | ||||||||
| Other Expense | ||||||||
| Pretax Income | ||||||||
| Tax Provision | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income (Loss) | (11,823) | (7,718) | (10,083) | (10,561) | (11,209) | (14,004) | (18,838) | (7,229) |
| Earnings Per Share (Basic) | (0.65) | (0.50) | (0.60) | (0.66) | (0.87) | (1.15) | (1.39) | (0.64) |
| Earnings Per Share (Diluted) | (0.65) | (0.50) | (0.60) | (0.66) | (0.87) | (1.15) | (1.39) | (0.64) |
| Weighted Average Shares Outstanding (Basic) | 18,212 | 15,313 | 16,692 | 16,059 | 12,951 | 12,203 | 13,582 | 11,285 |
| Weighted Average Shares Outstanding (Diluted) | 18,212 | 15,313 | 16,692 | 16,059 | 12,951 | 12,203 | 13,582 | 11,285 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About ELTX
Elicio Therapeutics, Inc. (NASDAQ: ELTX) is a stock listed on the Nasdaq Stock Market under the ticker symbol ELTX. It last traded at $1.75 (Oct 29, 2026, 4:00 PM ET), down 5.4% on the day. That gives Elicio Therapeutics a market capitalisation of $50.1M.
Over the past 52 weeks ELTX has traded between $1.44 and $16.00.
For the quarter ended Mar 31, 2026 it reported a net loss of $11.8M.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Mar 31, 2026 | — | -$11.8M |
| Dec 31, 2025 | — | -$7.7M |
| Sep 30, 2025 | — | -$10.1M |
| Jun 30, 2025 | — | -$10.6M |
From Elicio Therapeutics’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…